Medicare Cancer Drug Costs Not Linked to Clinical Value
TOPLINE: A new analysis suggests that Medicare spending on anticancer drugs is not based on a drug’s clinical value, highlighting “a misalignment between drug pricing and the clinical benefits they offer.” METHODOLOGY: Medicare typically accepts the drug …